Radiogenomics and Imaging Phenotypes in Glioblastoma: Novel Observations and Correlation with Molecular Characteristics

Current Neurology and Neuroscience Reports

Volumn 15, Issue 1, 2015, Pages

  Ellingson, Benjamin M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California   (United States)

Author keywords

GBM; Imaging genomics; Imaging phenotypes; Radiogenomics

Indexed keywords

CLINICAL FEATURE; CORRELATIONAL STUDY; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; DISEASE ASSOCIATION; GENOMICS; GLIOBLASTOMA; HISTOLOGY; HUMAN; NEUROIMAGING; NONHUMAN; PERFUSION WEIGHTED IMAGING; RADIOGENOMICS; RADIOGRAPHY; REVIEW; TUMOR LOCALIZATION; TUMOR VOLUME; ANIMAL; BRAIN; BRAIN TUMOR; GENETICS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHENOTYPE; PROCEDURES;

ANIMALS; BRAIN; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; PHENOTYPE; TUMOR BURDEN;

EID: 84926244656     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-014-0506-0     Document Type: Review

References (99)

1. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol. 2013;15 Suppl 2: ii1–56.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.
3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.
4. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110. Defines prognostically important gene expression subtypes in GBM.
5. Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol. 2010;12:116–21.
6. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350–4.
7. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003. Study demonstrates significant therapeutic benefit of temozolomide therapy in MGMT promoter methylated GBM.
8. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9:157–73. Defines prognostically important gene expression subtypes of GBM.
9. Pierallini A, Bonamini M, Pantano P, Palmeggiani F, Raguso M, Osti MF, et al. Radiological assessment of necrosis in glioblastoma: variability and prognostic value. Neuroradiology. 1998;40:150–3.
10. Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol. 1996;27:65–73.
11. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95:190–8.
12. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol. 2005;26:2466–74. First study to define radiographic descriptive features for use in radiogenomic analysis. Forms the basis of the VASARI feature set used by TCGA.
13. Ellingson BM, Lai A, Harris RJ, Selfridge JM, Yong WH, Das K, et al. Probabilistic radiographic atlas of glioblastoma phenotypes. AJNR Am J Neuroradiol. 2013;34:533–40. Study correlates tumor location, volumes, and composition with clinical, molecular, genomic, and interventional phenotypes in >500 GBM patients.
14. Hobbs SK, Shi G, Homer R, Harsh G, Atlas SW, Bednarski MD. Magnetic resonance image-guided proteomics of human glioblastoma multiforme. J Magn Reson Imaging. 2003;18:530–6.
15. Rees JH, Smirniotopoulos JG, Jones RV, Wong K. Glioblastoma multiforme: radiologic-pathologic correlation. Radiographics. 1996;16:1413–38. Quiz 1462–1413. One of the first studies to explicitly define radiographic–pathologic correlations in GBM.
16. Russell SM, Elliott R, Forshaw D, Golfinos JG, Nelson PK, Kelly PJ. Glioma vascularity correlates with reduced patient survival and increased malignancy. Surg Neurol. 2009;72:242–6. Discussion 246–247.
17. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell. 2009;15:167–70.
18. Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg. 1987;66:865–74.
19. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29:15–8.
20. Pope WB, Chen JH, Dong J, Carlson MR, Perlina A, Cloughesy TF, et al. Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. Radiology. 2008;249:268–77. One of the first radiogenomic studies in GBM.
21. Damadian R. Tumor detection by nuclear magnetic resonance. Science. 1971;171:1151–3.
22. Hoehn-Berlage M, Tolxdorff T, Bockhorst K, Okada Y, Ernestus RI. In vivo NMR T2 relaxation of experimental brain tumors in the cat: a multiparameter tissue characterization. Magn Reson Imaging. 1992;10:935–47.
23. Oh J, Cha S, Aiken AH, Han ET, Crane JC, Stainsby JA, et al. Quantitative apparent diffusion coefficients and T2 relaxation times in characterizing contrast enhancing brain tumors and regions of peritumoral edema. J Magn Reson Imaging. 2005;21:701–8.
24. Levin VA, Crafts DC, Norman DM, Hoffer PB, Spire JP, Wilson CB. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J Neurosurg. 1977;47:329–35.
25. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–14.
26. Macdonald DR, Cascino TL, Schold Jr SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277–80.
27. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963–72.
28. Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys. 1993;26:239–44.
29. Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med. 2005;353:811–22.
30. Wechsler-Reya R, Scott MP. The developmental biology of brain tumors. Annu Rev Neurosci. 2001;24:385–428.
31. Zlatescu MC, TehraniYazdi A, Sasaki H, Megyesi JF, Betensky RA, Louis DN, et al. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res. 2001;61:6713–5.
32. Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev. 2000;14:994–1004.
33. Poppleton H, Gilbertson RJ. Stem cells of ependymoma. Br J Cancer. 2007;96:6–10.
34. Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol. 2011;29:4482–90.
35. Ellingson BM, Cloughesy TF, Pope WB, Zaw TM, Phillips H, Lalezari S, et al. Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas. Neuroimage. 2012;59:908–16.
36. Lim DA, Cha S, Mayo MC, Chen MH, Keles E, VandenBerg S, et al. Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol. 2007;9:424–9.
37. Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, et al. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol. 2012;33:1349–55.
38. Diehn M, Nardini C, Wang DS, McGovern S, Jayaraman M, Liang Y, et al. Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A. 2008;105:5213–8.
39. Naeini KM, Pope WB, Cloughesy TF, Harris RJ, Lai A, Eskin A, et al. Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. Neuro Oncol. 2013;15:626–34. Study demonstrates how simple volumes and tumor composition can be used to identify the mesenchymal gene expression subtype of GBM.
40. Zinn PO, Mahajan B, Sathyan P, Singh SK, Majumder S, Jolesz FA, et al. Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. PLoS One. 2011;6:e25451. One of the first studies to identify novel genomic signatures solely on the basis of predefined radiographic phenotypes.
41. Zinn PO, Sathyan P, Mahajan B, Bruyere J, Hegi M, Majumder S, et al. A novel volume-age-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNA-gene signature. PLoS One. 2012;7:e41522.
42. Gutman DA, Cooper LA, Hwang SN, Holder CA, Gao J, Aurora TD, et al. MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology. 2013;267:560–9.
43. Kuo MD, Gollub J, Sirlin CB, Ooi C, Chen X. Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma. J Vasc Interv Radiol. 2007;18:821–31.
44. Rutman AM, Kuo MD. Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur J Radiol. 2009;70:232–41.
45. Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D. Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol. 2005;15:297–310.
46. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007;8:610–22.
47. Rome C, Arsaut J, Taris C, Couillaud F, Loiseau H. MMP-7 (matrilysin) expression in human brain tumors. Mol Carcinog. 2007;46:446–52.
48. Leo C, Giaccia AJ, Denko NC. The hypoxic tumor microenvironment and gene expression. Semin Radiat Oncol. 2004;14:207–14.
49. Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE, et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell. 2002;13:1977–2000.
50. Channin DS, Mongkolwat P, Kleper V, Rubin DL. The annotation and image mark-up project. Radiology. 2009;253:590–2.
51. Channin DS, Mongkolwat P, Kleper V, Sepukar K, Rubin DL. The caBIG annotation and image Markup project. J Digit Imaging. 2010;23:217–25.
52. Colen RR, Vangel M, Wang J, Gutman DA, Hwang SN, Wintermark M, et al. Imaging genomic mapping of an invasive MRI phenotype predicts patient outcome and metabolic dysfunction: a TCGA glioma phenotype research group project. BMC Med Genomics. 2014;7:30.
53. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33.
54. Dang CV. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med. 2013;3.
55. Kaadige MR, Elgort MG, Ayer DE. Coordination of glucose and glutamine utilization by an expanded Myc network. Transcription. 2010;1:36–40.
56. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol. 2008;26:101–6.
57. Dang CV. MYC on the path to cancer. Cell. 2012;149:22–35.
58. Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst. 2000;92:2029–36.
59. Bode MK, Ruohonen J, Nieminen MT, Pyhtinen J. Potential of diffusion imaging in brain tumors: a review. Acta Radiol. 2006;47:585–94.
60. Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quinsey C, LaViolette PS, et al. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging. 2010;31:538–48.
61. Sugahara T, Korogi Y, Kochi M, Ikushima I, Shigematu Y, Hirai T, et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging. 1999;9:53–60.
62. Lyng H, Haraldseth O, Rofstad EK. Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med. 2000;43:828–36.
63. Guo AC, Cummings TJ, Dash RC, Provenzale JM. Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology. 2002;224:177–83.
64. Hayashida Y, Hirai T, Morishita S, Kitajima M, Murakami R, Korogi Y, et al. Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. AJNR Am J Neuroradiol. 2006;27:1419–25.
65. Kinoshita M, Hashimoto N, Goto T, Kagawa N, Kishima H, Izumoto S, et al. Fractional anisotropy and tumor cell density of the tumor core show positive correlation in diffusion tensor magnetic resonance imaging of malignant brain tumors. Neuroimage. 2008;43:29–35.
66. Kidwell CS, Alger JR, Di Salle F, Starkman S, Villablanca P, Bentson J, et al. Diffusion MRI in patients with transient ischemic attacks. Stroke. 1999;30:1174–80.
67. Pierpaoli C, Alger JR, Righini A, Mattiello J, Dickerson R, Des Pres D, et al. High temporal resolution diffusion MRI of global cerebral ischemia and reperfusion. J Cereb Blood Flow Metab. 1996;16:892–905.
68. Verheul HB, Balazs R, van der Sprenkel JW B, Tulleken CA, Nicolay K, Tamminga KS, et al. Comparison of diffusion-weighted MRI with changes in cell volume in a rat model of brain injury. NMR Biomed. 1994;7:96–100.
69. Wintersperger BJ, Runge VM, Biswas J, Reiser MF, Schoenberg SO. Brain tumor enhancement in MR imaging at 3 Tesla: comparison of SNR and CNR gain using TSE and GRE techniques. Invest Radiol. 2007;42:558–63.
70. Chang SC, Lai PH, Chen WL, Weng HH, Ho JT, Wang JS, et al. Diffusion-weighted MRI features of brain abscess and cystic or necrotic brain tumors: comparison with conventional MRI. Clin Imaging. 2002;26:227–36.
71. Farrell CJ, Hoh BL, Pisculli ML, Henson JW, FG 2nd B, Curry Jr WT. Limitations of diffusion-weighted imaging in the diagnosis of postoperative infections. Neurosurgery. 2008;62:577–83. Discussion 577–583.
72. Kastrup O, Wanke I, Maschke M. Neuroimaging of infections. NeuroRx. 2005;2:324–32.
73. Barajas Jr RF, Phillips JJ, Parvataneni R, Molinaro A, Essock-Burns E, Bourne G, et al. Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. Neuro Oncol. 2012;14:942–54. One of the first studies to use image-guided biopsies to examine the association between physiologic imaging features and histopathology.
74. Basser PJ, Pierpaoli C. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson B. 1996;111:209–19.
75. Basser PJ. New histological and physiological stains derived from diffusion-tensor MR images. Ann N Y Acad Sci. 1997;820:123–38.
76. Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009;252:182–9.
77. Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol. 2012;108:491–8.
78. Pope WB, Lai A, Mehta R, Kim HJ, Qiao J, Young JR, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol. 2011;32:882–9.
79. Phillips H, Sandmann T, Li C, Cloughesy TF, Chinot OL, Wick W, et al. Correlation of molecular subtypes with survival in AVAglio (bevacizumab and radiotherapy and temozolomide for newly diagnosed glioblastoma). J Clin Oncol 2014;32: suppl; abstr 2001.
80. Pope WB, Mirsadraei L, Lai A, Eskin A, Qiao J, Kim HJ, et al. Differential gene expression in glioblastoma defined by ADC histogram analysis: relationship to extracellular matrix molecules and survival. AJNR Am J Neuroradiol. 2012;33:1059–64. One of the first studies to explore differences in gene expression on the basis of diffusion MR phenotypes.
81. Drabycz S, Roldan G, de Robles P, Adler D, McIntyre JB, Magliocco AM, et al. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage. 2010;49:1398–405.
82. Meier P, Zierler KL. On the theory of the indicator-dilution method for measurement of blood flow and volume. J Appl Physiol. 1954;6:731–44.
83. Stewart GN. Researches on the circulation time and on the influences which affect it. J Physiol. 1897;22:159–83.
84. Rosen BR, Belliveau JW, Vevea JM, Brady TJ. Perfusion imaging with NMR contrast agents. Magn Reson Med. 1990;14:249–65.
85. Villringer A, Rosen BR, Belliveau JW, Ackerman JL, Lauffer RB, Buxton RB, et al. Dynamic imaging with lanthanide chelates in normal brain: contrast due to magnetic susceptibility effects. Magn Reson Med. 1988;6:164–74.
86. Rosen BR, Belliveau JW, Buchbinder BR, McKinstry RC, Porkka LM, Kennedy DN, et al. Contrast agents and cerebral hemodynamics. Magn Reson Med. 1991;19:285–92.
87. Belliveau JW, Kennedy Jr DN, McKinstry RC, Buchbinder BR, Weisskoff RM, Cohen MS, et al. Functional mapping of the human visual cortex by magnetic resonance imaging. Science. 1991;254:716–9.
88. Kwong KK, Belliveau JW, Chesler DA, Goldberg IE, Weisskoff RM, Poncelet BP, et al. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Natl Acad Sci U S A. 1992;89:5675–9.
89. Edelman RR, Mattle HP, Atkinson DJ, Hill T, Finn JP, Mayman C, et al. Cerebral blood flow: assessment with dynamic contrast-enhanced T2*-weighted MR imaging at 1.5 T. Radiology. 1990;176:211–20.
90. Hacklander T, Reichenbach JR, Hofer M, Modder U. Measurement of cerebral blood volume via the relaxing effect of low-dose gadopentetate dimeglumine during bolus transit. AJNR Am J Neuroradiol. 1996;17:821–30.
91. Cha S, Johnson G, Wadghiri YZ, Jin O, Babb J, Zagzag D, et al. Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology. Magn Reson Med. 2003;49:848–55.
92. Pathak AP, Schmainda KM, Ward BD, Linderman JR, Rebro KJ, Greene AS. MR-derived cerebral blood volume maps: issues regarding histological validation and assessment of tumor angiogenesis. Magn Reson Med. 2001;46:735–47.
93. Badruddoja MA, Krouwer HG, Rand SD, Rebro KJ, Pathak AP, Schmainda KM. Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRI cerebral blood volume maps. Neuro Oncol. 2003;5:235–43.
94. Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, Weisskoff RM. NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med. 1998;40:793–9.
95. Lev MH, Ozsunar Y, Henson JW, Rasheed AA, Barest GD, Harsh GR, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol. 2004;25:214–21.
96. Cha S, Tihan T, Crawford F, Fischbein NJ, Chang S, Bollen A, et al. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol. 2005;26:266–73.
97. Whitmore RG, Krejza J, Kapoor GS, Huse J, Woo JH, Bloom S, et al. Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging. J Neurosurg. 2007;107:600–9.
98. Cooper LA, Gutman DA, Long Q, Johnson BA, Cholleti SR, Kurc T, et al. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS One. 2010;5:e12548.
99. Jain R, Poisson L, Narang J, Gutman D, Scarpace L, Hwang SN, et al. Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. Radiology. 2013;267:212–20.